



We count on them for comfort, so provide—  
**Superior protection that you can count on.**


- **SUPERIOR EFFICACY** demonstrated vs multiple FeLV vaccines, including PUREVAX® Recombinant FeLV<sup>1,2</sup>
- The **ONLY** FeLV vaccine labeled to **PREVENT** persistent viremia<sup>3</sup>
- The **ONLY** USDA-licensed **2-YEAR DURATION OF IMMUNITY** (DOI) FeLV vaccine<sup>3</sup>  
— Ideal for adherence to AAFP guidelines<sup>4</sup>
- The **ONLY** vaccine to demonstrate efficacy over the long-term in a co-mingling study<sup>3</sup>  
— Mimicking **REAL LIFE** conditions
- **PROVEN SAFETY** profile<sup>3</sup>  
— 99% reaction-free in ongoing surveillance involving millions of doses<sup>3</sup>

## Nobivac®:FeLV

*Protection that lasts*

# Superior protection that helps your clients feel comfortable


Proven protection against all stages of FeLV.<sup>5,6</sup>



- ≥92% protection against transient viremia, latent infection, and persistent viremia<sup>5,6</sup>

The **ONLY** feline leukemia vaccine labeled to **PREVENT persistent viremia**<sup>3</sup>

Demonstrated protection in real-life, mimicking conditions for more than 3 years.<sup>3</sup>



- For more than 3 years in real-life conditions, 60 vaccinated cats were housed with 16 cats that had persistent viremia and were actively shedding virulent FeLV<sup>3</sup>



## 100% protection confirmed in 2 independent studies.<sup>1,2</sup>

**Comparative study** Nobivac® Feline 2-FeLV provides effective protection against FeLV challenge<sup>1</sup>

Experimental group	<i>n</i>	Persistent antigenemia/ viremia	Preventable fraction
Fel-O-Vax Lv-K®	8	0	100%
<b>Nobivac® Feline 2-FeLV</b>	<b>8</b>	<b>0</b>	<b>100%</b>
LEUKOCELL 2®	8	3	57%
Protex®-FeLV†	8	5	
Unvaccinated controls	8	7	N/A

**Comparative study** Nobivac® Feline 2-FeLV provides superior efficacy against PUREVAX® FeLV<sup>2</sup>


Experimental group	<i>n</i>	Persistent viremia	Preventable fraction
<b>Nobivac® Feline 2-FeLV</b>	<b>11</b>	<b>0</b>	<b>100%</b>
PUREVAX® Recombinant FeLV	10	5	45%
Unvaccinated	11	10	N/A

*“The results of this blind study, with sufficient sample size and the requisite controls, showed that cats appropriately vaccinated with Nobivac® Feline 2-FeLV were significantly protected from an oronasal FeLV challenge. This study is reinforcing evidence that whole inactivated viral vaccines can protect cats from both active and latent FeLV infections.”<sup>3</sup>*

— Andrea N. Torres, DVM, PhD, Dipl


Products are registered trademarks of their respective manufacturers.  
 \* Previously known as Fevaxyn® FeLV.  
 † Vaccine is no longer sold.

## Significant protection from persistent viremia<sup>2</sup>



- At week 12 post-challenge, cats in Group A showed no FeLV p27 in serum<sup>2</sup>
- There was no significant difference ( $P>0.063$ ) in FeLV p27 levels between Groups B and C<sup>2</sup>

## Superior results in FeLV proviral DNA and plasma viral RNA persistence tests<sup>\*2</sup>



- At week 9 post-challenge, Group A had significantly lower proviral DNA loads than Group B from week 6 to 9 ( $P<0.02$ ) and significantly lower plasma viral RNA loads from week 7 to 9 ( $P<0.01$ )<sup>2</sup>

\*At week 9 post-challenge.

# Facts about Feline Injection-Site Sarcoma (FISS)

**FISS** occurs very infrequently— $\leq 1/10,000$  injections<sup>4</sup>

- **No published evidence** that non-adjuvanted vaccines are safer than adjuvanted vaccines with respect to tumorigenesis risk<sup>7</sup>
- **No links** between induced or injection site sarcomas and specific materials can be confirmed<sup>4,8</sup>
- In 2012, VMD\* received a total of 26 reports of FISS associated with vector vaccines, non-adjuvanted live attenuated vaccines, mixed live bacterial vaccines, viral vaccines, and inactivated vaccines<sup>9</sup>

*"All immunization products are likely associated with this induced tumor, and recombinant vaccines are not free of risk."<sup>8</sup>*

— L.D. McGill, DVM, PhD, DACVP  
Medical Director and Veterinary Pathologist  
Animal Reference Pathology  
Salt Lake City, Utah



**Nobivac<sup>®</sup> Feline 2-FelV has a safety profile you can count on**

The **ONLY** USDA-licensed **2-year DURATION OF IMMUNITY (DOI) FeLV vaccine<sup>3</sup>**

- Extended coverage is ideal for adhering to AAFP guidelines
- 99% reaction-free in ongoing surveillance involving millions of doses<sup>3</sup>

**Nobivac<sup>®</sup>:FeLV**

*Protection that lasts*











\*VMD=Veterinary Medicines Directorate (UK Regulatory Authority).





# Meet your patients' individual needs with our complete line of feline vaccines

## Feline vaccine reference chart

	Rhinotracheitis (Herpesvirus 1) (MLV)*	Calicivirus (MLV)*	Panleukopenia (MLV)*	Chlamydophila (ML†)	Leukemia (Killed)	Bordetella (AL†)	Rabies (Killed)	Non-adijuvanted
<b>1-year vaccines</b>								
 Nobivac® Feline 1-HCP	●	●	●					●
 Nobivac® Feline 1-HCPCh	●	●	●	●				●
 Nobivac® Feline 1-HCP+FeLV	●	●	●		●			
 Nobivac® Feline 1-HCPCh+FeLV	●	●	●	●	●			
 Nobivac® 1-Rabies						●		
<b>2-year vaccines</b>								
 Nobivac® Feline 2-FeLV					●			
<b>3-year vaccines</b>								
 Nobivac® Feline 3-HCP	●	●	●					●
 Nobivac® 3-Rabies						●		
 Nobivac® 3-Rabies CA						●		
<b>Intranasal vaccines</b>								
 Nobivac® Feline-Bb					●			●

Colored dot(s) next to product names indicate cap color(s).

\* Modified live virus. † Modified live. ‡ Avirulent live.

To learn more, contact your Merck Animal Health sales representative, visit [www.merck-animal-health-usa.com](http://www.merck-animal-health-usa.com), or give us a call.

Customer Service **1-800-521-5767**  
(Monday – Friday, 8:00 AM – 6:00 PM EST)

Technical Services **1-800-224-5318**  
(Monday – Friday, 8:30 AM – 5:00 PM EST)

Vaccine Protocol Help Line **1-866-437-7955**  
(Monday – Friday, 8:00 AM – 5:00 PM EST)

**References:** 1. Torres AN, O'Halloran KP, Larson LJ, Schultz RD, Hoover EA. Feline leukemia virus immunity induced by whole inactivated virus vaccination. *Vet Immunol Immunopathol.* 2010;134(1-2):122-131. 2. Patel M, Carritt K, Lane J, Jayappa H, Stahl M. Comparative efficacy of feline leukemia virus inactivated whole virus vaccine and canarypox virus-vectored vaccine by modern molecular assays and conventional parameters. *J Vet Intern Med.* 2014;28:1060-1061. 3. Data on file, Merck Animal Health. Summit, NJ. 2013. 4. American Association of Feline Practitioners. AAFP 2013 feline vaccination advisory panel report. *J Feline Med Surgery.* 2013;15:785-808. 5. Pederson NC. Immunogenicity and efficacy of a commercial feline leukemia vaccine. *J Vet Intern Med.* 1993;7(1):34-39. 6. Hines DL, Cutting JA, Dietrich DA, Walsh JA. Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection. *J Am Vet Med Assoc.* 1991;199(10):1428-1430. 7. Srivastav A, Kass PH, McGill KD, Farver TB, Kent MS. Comparative vaccine-specific and other injectable-specific risks of injection-site sarcomas in cats. *JAVMA.* 2012;241(5):595-602. 8. McGill LD. Induced or injection site sarcomas: what do we really know? Merck Animal Health. 2013. 9. Davis G, Rooney A, Cooles S, Evans G. Suspected adverse events, 2012. *Vet Rec.* 2013;173:573-576.

Copyright © 2014 Intervet Inc., a subsidiary of Merck & Co., Inc. All rights reserved. Intervet Inc. d/b/a Merck Animal Health, Summit, NJ 07901. US/NFL/0614/0003 12819

Merck Animal Health  
556 Morris Avenue  
Summit, New Jersey 07901  
USA  
Phone: 800 521 5767  
[www.merck-animal-health-usa.com](http://www.merck-animal-health-usa.com)

